“没有最贵,只有更贵”,这个俗语在医药界同样适用。今年8月,蓝鸟生物(bluebird bio, Inc. ,Nasdaq: BLUE)β-地中海贫血基因疗法Zynteglo(beti-cel)定价为280万,超过诺华的基因疗法Zolgensma(定价210万美元),成为了当时的“史上最贵药”。仅一个月时间,该公司第2款基因疗法SKYSONA®(elivaldogene autotemcel,...
Source Link“没有最贵,只有更贵”,这个俗语在医药界同样适用。今年8月,蓝鸟生物(bluebird bio, Inc. ,Nasdaq: BLUE)β-地中海贫血基因疗法Zynteglo(beti-cel)定价为280万,超过诺华的基因疗法Zolgensma(定价210万美元),成为了当时的“史上最贵药”。仅一个月时间,该公司第2款基因疗法SKYSONA®(elivaldogene autotemcel,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.